series-a
Stage
1
Investors
About
Nectin Therapeutics is developing immunotherapeutic biologic drugs that target receptors in the nectin protein family to treat solid and hematological cancers. The company is advancing a pipeline of targeted antibodies designed to block tumor inhibitory pathways and enable immune cells to eliminate cancer cells.
Explore Nectin Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.